LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Gilead Sciences Inc.

Gilead Sciences Inc.

Suletud

Sektor Tervishoid

78.71 0.01

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

78.47

Max

78.83

Põhinäitajad
By Trading Economics
Sissetulek	5.8B 1.6B
Müük	314M 7B
P/E Sektori keskmine	190.58 103.001
Aktsiakasum	2.01
Kasumimarginaal	23.057
Töötajad	18,000
EBITDA	6.5B 3B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+5.73 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. nov 2024
Järgmine dividendimakse kuupäev	27. sept 2024
Järgmine aktsia dividendi kuupäev (ex-date)	13. sept 2024

Turustatistika
By TradingEconomics
Turukapital	99B
Eelmine avamishind	78.7
Eelmine sulgemishind	78.71

Uudiste sentiment

By Acuity

67%

33%

53 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

77.12 / 79.4 Toetus ja vastupanu

Gilead Sciences Inc. Graafik

Seotud uudised

8. aug 2024, 20:49 UTC

Tulu

Gilead Sciences Posts Higher 2Q Profit, Revenue on Increased Sales

25. apr 2024, 20:39 UTC

Tulu

Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges

28. märts 2024, 13:35 UTC

Suurimad hinnamuutused turgudel

Xilio Shares Take Flight Premarket After Gilead Deal

9. aug 2024, 20:12 UTC

Tulu

Gilead Stock Dips As 'Non-Core' Products Drive Its Second-Quarter Beat -- IBD

9. aug 2024, 09:00 UTC

Peamised uudised

These Stocks Are Moving the Most Today: Expedia, Paramount, E.l.f. Beauty, Doximity, Rocket Lab, Gilead, and More -- Barrons.com

8. aug 2024, 20:03 UTC

Peamised uudised

Tulu

Gilead Boosts Earnings Outlook as Stock Battles Back from Cancer Disappointment -- Barrons.com

8. aug 2024, 20:03 UTC

Tulu

Gilead Sciences Sees FY24 EPS 0c-EPS 30c >GILD

8. aug 2024, 20:03 UTC

Tulu

Gilead Sciences Sees 3Q Adj EPS $3.60-Adj EPS $3.90 >GILD

8. aug 2024, 20:02 UTC

Tulu

Gilead Sciences 2Q Rev $7B >GILD

8. aug 2024, 20:02 UTC

Tulu

Gilead Sciences 2Q Adj EPS $2.01 >GILD

8. aug 2024, 20:02 UTC

Tulu

Gilead Sciences 2Q EPS $1.29 >GILD

8. aug 2024, 20:02 UTC

Tulu

Gilead Sciences 2Q Net $1.61B >GILD

20. juuni 2024, 20:16 UTC

Peamised uudised

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20. juuni 2024, 18:09 UTC

Peamised uudised

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20. juuni 2024, 16:24 UTC

Tulu

Gilead Stock Jumps. Its Twice-Yearly Shot Prevents HIV. -- Barrons.com

20. juuni 2024, 11:00 UTC

Peamised uudised

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- WSJ

25. apr 2024, 20:41 UTC

Tulu

Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again -- IBD

25. apr 2024, 20:10 UTC

Tulu

Gilead Sciences Cuts FY View To Adj EPS $3.45-Adj EPS $3.85 >GILD

25. apr 2024, 20:10 UTC

Tulu

Gilead Sciences Cuts FY View To EPS 10c-EPS 50c >GILD

25. apr 2024, 20:09 UTC

Tulu

Gilead Sciences Backs FY Product Sales $27.1B-$27.5B >GILD

25. apr 2024, 20:08 UTC

Tulu

Gilead Closed CymaBay Acquisition Resulting in $3.9 B Acquired IPR&D Chg, or $3.14 Diluted EPS Impact

25. apr 2024, 20:07 UTC

Tulu

Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss? -- IBD

25. apr 2024, 20:03 UTC

Peamised uudised

Tulu

Gilead Beats Earnings Expectations After Rocky Quarter -- Barrons.com

25. apr 2024, 20:02 UTC

Tulu

Gilead Sciences 1Q Loss $4.17B >GILD

25. apr 2024, 20:02 UTC

Tulu

Gilead Sciences 1Q Loss/Shr $3.34 >GILD

25. apr 2024, 20:02 UTC

Tulu

Gilead Sciences 1Q Adj Loss/Shr $1.32 >GILD

25. apr 2024, 20:02 UTC

Tulu

Gilead Sciences 1Q Rev $6.7B >GILD

22. märts 2024, 13:18 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences Announces Completion Of Acquisition Of CymaBay >GILD CBAY

11. märts 2024, 12:26 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Other Conditions Remain to Be Satisfied, Including, Among Others, a Minimum Tender of Shrs of Common Stk of CymaBay Representing a Majority of the Total Number of Outstanding Shrs of Common Stk of CymaBay >GILD

11. märts 2024, 12:26 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Expiration of the HSR Waiting Period Satisfies One of the Conditions to Consummate the Tender Offer >GILD

Võrdlus sarnastega

Hinnamuutus

Gilead Sciences Inc. Prognoos

Hinnasiht

By TipRanks

5.73% tõus

12 kuu keskmine prognoos

Keskmine 83.28 USD 5.73%

Kõrge 95 USD

Madal 70 USD

Põhineb 21 Wall Streeti analüütiku instrumendi Gilead Sciences Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

21 ratings

Osta

Hoia

Müü

Põhineb 21 analüütiku instrumendi Gilead Sciences Inc. aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

77.12 / 79.4Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

53 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gilead Sciences Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.